Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Name: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
Published: 2006
License: Public Domain

Novartis · 2006

ClinicalTrials.gov · Datasets · License: Public Domain · 2006

Open Source ↗

influenza

pandemic influenza disease, influenza, pandemic influenza, influenza vaccine, adjuvanted influenza vaccine, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Related documents